Member Info for Barnacle

Hi Shandypants2,

The company has stated in it's Final Year results from July, that: "the Company believes it will get cash flow positive during 2024 without the need for further funding." and also :

“an increased emphasis has been placed on achieving a cash flow generative position in 2024. The operational cash burn has been significantly reduced through various initiatives including the roll out of the enhanced 'BrandShield 3.0' platform to the Company's clients. This has allowed greater automation to be achieved leading to wider re-structuring within certain areas of the Company, particularly within the enforcement division. Other cost cutting has been achieved including a reduction in cloud based costs. The Company also holds legacy investment assets that it is seeking to dispose of in an orderly way. Opportunities may arise to dispose of these however the Company is not reliant on this in a going concern scenario. In addition, the directors have undertaken sensitivity reviews of the forecasts to model the effects of lower than budgeted growth and believe that cost reductions would be achievable if needed (albeit to the detriment of the Group's long term strategy) if required to avoid the need for a fundraise within the next 12 months. These measures would include if required the Directors deferring an element of their salaries. As such, the Directors consider that the Group will have access to adequate resources to meet operational requirements for at least 12 months from the date of approval of these financial statements.

I'm guessing that would be why Sir Terence Leahy and William Currie were prepared to buy more shares back in May, otherwise why risk dilution?

Shh, the longer the better... just keep accumulating ;0)

Https://www.voxmarkets.co.uk/articles/q-a-with-dr-tom-oakley-of-feedback-plc-5a69d6c

From Linkedin:

Delighted to announce we have been awarded 2023's Leading Innovator in Medical Imaging Technology - London by Global Health & Pharma's Global Excellence Awards.

Been following MAST for a while with interest. Once the Joint Agreement has been signed off in a couple of weeks, I'm expecting the share price to significantly improve. I would also suspect that they have been holding off from publishing project news until this is done, so would expect updates to follow. Should see this heading back to 3p in the next few weeks.

Https://www.linkedin.com/feed/update/urn:li:activity:7079425428213387264/

Interesting article posted today by Cap XX on their Linkedin page:

https://lnkd.in/eYTECe5R

Good find ndr50, would certainly tie in with what Bleepa has to offer, and did you see what it is worth?

Estimated Value £975,800,000 Excluding VAT

Wouldn't mind some of that!

Yep, looking good Roley, trading should only be improving since last year, shares price will improve accordingly.

Sir Terence Leahy and Mr William Christopher Currie have increased their holdings, explains yesterdays large buys. A big vote of confidence in Brandshield, exciting times ahead I feel......

So if the WeShop share price is £5.95, I calculate that would put Brandshields holding at a value of $7m. The company is expected to Turnover US$13M this year, and become profit making, plus with it's WeShop holding, makes it a screaming buy.

The lock in period has now past, which might have something to do with it. I also noticed that the latest transaction of WeShop shares went for £5.95 which would place Brandshields holding at a much higher value.

BrandShield holds 508,508 shares in WeShop Limited. This represents around 10.5% of the currently issued share capital in WeShop Limited. Should a £9m convertible loan note in WeShop Limited convert then the Company’s holding would reduce to around 5.3%. WeShop Holdings Limited is currently trading on the JP Jenkins matched bargain trading platform with most recent trades being at £3.50 per share. Taking this share price then the Net Asset Value of WeShop Limited would be £116m and the potential NAV per share would be £24.05 for currently issued shares or £12.09 for shares issued following conversion of the CLNs. The value of BrandShield’s holding could be derived at £12.2m or £6.2m respectively in those scenarios, however the Board does not believe that it is prudent to attach such a valuation at this stage given the relatively small trading volume of WeShop Holdings on JP Jenkins, the fact that the WeShop main marketing effort has not been fully launched yet and the fact that there are likely to be some taxation liabilities and administrative costs associated with WeShop Limited which will be deducted from any shares issued to underlying shareholders in specie. The lock in period to May 2023 would also require a discount to be applied to any derived valuation. As such the Board has continued to hold the value of the investment in WeShop Limited at cost, that being $4,112,107.

Apologies if already posted: Modern Clinical Communications Solution and Implementation Partner, closing date tomorrow.

https://bidstats.uk/tenders/2023/W19/798294020

Description:

A Bleep communication system is currently being utilised at The Dudley Group NHS Foundation Trust (DGFT).

However, in 2019 the then Health Secretary called for the phasing out of this method of communication.

Modern technology facilitates the need for team-based communication, image facilitation, and task assignment.

Bleeps on the other hand require medics to seek out landline phones to then go through a switch board and manually telephone everyone involved which negatively impacts efficient clinical care.

In line with our Digital and People Plans, a new communication solution is needed to improve productivity. To achieve digital maturity, modern clinical communication solutions is a key element to ensure that there is a sustainable patient flow through the treatment process.

Improving the flow of patients is in line with a key strategic objective of ensuring patient care.

As a result of the recent pandemic, there is now a significant backlog of patients across clinical domains, meaning that ensuring there is adequate communication and flow is essential to ensure the Trust meets clinical demands. DGFT wish to embark on a programme of work to deliver enhancements to our clinical communication methodologies which will underpin the efficient flow of patients between clinical teams.

A partner is required to provide a full end-to-end set of professional in-house Project Services relating to Modern Clinical Communication and offer insight expertise into linking this with the current digital infrastructure at DGFT.

Some big trades, could be connected to WeShop?

Looking forward to the Investor Meet Presentation next week, expecting a positive update on H1. At a market cap of only £1.8M there is plenty of room for the share price to climb back to it's pre-covid levels. Expecting a steady climb from these levels.

I would suspect that the decision to sell Stevenage Circuits is in large part to do with Andrew Lapping's arrival, a shrewder business man than Philip Johnston, with a cv to prove it. From his initial comments, it's clear that he see's the value of the company being in IHT and it's huge potential in the EV market. Best to focus all efforts on the new world class production facility, and get those machine working to full capacity! I think this is a case of thinking smart.

"I am delighted to take on the challenge of helping to lead Trackwise with my former Hyperdrive CEO Chris Pennison as we join the Trackwise Board. We bring industry experience to the Group with a track record of transitioning smart technology into a commercially viable and successful product.

"Prior to our participation in the Fundraising, Chris and I undertook significant referencing of the sales pipeline and the core technology. As a result, we believe there is significant potential for Trackwise and its IHT technology in the EV market."

"Whilst I recognise that the Fundraising has been difficult for existing shareholders, I would urge all to get behind us as we look to exploit the Company's world-class IP and production facilities.

"I want to close by reassuring all stakeholders that Trackwise has enormous potential but to realise its true value, we have to think and act smart in a very dynamic and rapidly expanding market."

I'm new to XPF, but have been impressed with their rollout of new sites, the focus they seem to have on customer service, and the 5 star reviews they consistently achieve across both offerings. I'm guessing there will be a trading update in a few weeks time when they post their full year accounts? Will be interesting to find out how Oxford Street is performing, amoungst others....

A positive step to focus on IHT, as this is where the future lies. From last years results :

We describe above our June 2021 delivery of a 72 metre long multilayer flex and we know of no other company worldwide that could have manufactured such a product. Such extreme length products are, by definition, unusual in nature, however the development know-how that has led to such a delivery is key to the ongoing development of our roll-to-roll, length-unlimited, length-agnostic, IHT manufacturing capability that we believe is our USP.

The development know-how and manufacturing assets have cross-sectoral applicability. Trackwise started its IHT journey in aerospace and the length-agnostic roll-to-roll manufacturing capability that we initially developed to deliver long aerospace circuits now allow us also to make smaller EV battery parts at scale. The EV learning is now feeding back into the manufacture of aerospace and medical products.

Almost all of our sales pipeline - for the EV, medical and aerospace sectors - has come to Trackwise from around the world because of our ability to deliver long flex; a globally unique manufacturing capability.

Double Belt Press (DBP)

With the (post year-end) delivery and commissioning of the Double Belt Press (DBP), the length-unlimited multilayer flex PCB manufacturing process envisaged in the original IHT patent* application in January 2012 has now been realised as an in-house capability. This is a major milestone for the business.

The DBP is a key strategic asset, providing a state-of-the-art capability to manufacture our own metal-clad laminates, as well as allowing us to bond together individual circuit layers to form the patented length-unlimited multilayer circuits.

Bringing this unique capability 'up to speed' is a key strategic priority. A number of customer developments have been held until such time as we have this capability in-house, and, more generally, our rate of development will now be able to speed up immeasurably.

Maybe a mixture of financial planning, balancing the books for last financial year, and the inclusion of more features to the Tender, in order to maximise the advantages of a new digital platform, after all it will be a big step for them...